Laboratory Action Plan for Emerging SARS-CoV-2 Variants

Clin Chem. 2021 Apr 29;67(5):720-723. doi: 10.1093/clinchem/hvab020.

Authors

Laura Filkins^{1

2}, Jeffrey A SoRelle^{1

2}, John Schoggins³, Jason Y Park^{1

2

4}

Affiliations

¹ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX.
² Department of Pathology and Laboratory Medicine, Children's Health System of Texas, Dallas, TX.
³ Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, TX.
⁴ McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX.

No abstract available

Keywords: B.1.1.7; COVID-19; SARS-CoV-2; VOC-202012/01; VUI-202012/01; coronavirus disease 2019.

MeSH terms

COVID-19 / diagnosis*
COVID-19 / genetics
COVID-19 Serological Testing / standards*
Humans
Laboratories / standards*
SARS-CoV-2 / genetics*

Grants and funding

DP1 AI158124/AI/NIAID NIH HHS/United States